AbbVie has announced two positive updates for Canadians living with UC, including those in Ontario and Alberta. SKYRIZI® (risankizumab) has been listed in Ontario (ON) and Alberta (AB) formularies for the treatment of moderately to severely active ulcerative colitis (UC). SKYRIZI® (risankizumab), an IL-23 inhibitor, received positive reimbursement recommendations for Crohn's disease (CD) and ulcerative colitis (UC).

AbbVie received a letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC in November 2025. To date, SKYRIZI® (risankizumab) has been listed for the treatment of UC on the public drug formularies in Quebec (Médicament d'exception), Nova Scotia (Exception Drug Status), Non-Insured Health Benefits (NIHB) (Limited Use), Prince Edward Island (Special Authorization), Alberta (Special Authorization) and Ontario (Exceptional Access Program). We are continuing our efforts to make sure SKYRIZI® (risankizumab) is accessible for patients with UC and listed on the public drug formularies across the country in a timely manner.

Canada's Drug Agency (CDA-AMC) has recommended SKYRIZI® (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met last November. Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease affecting the large intestine, causing persistent inflammation and ulceration of the colon's lining. Common symptoms include frequent diarrhea, abdominal pain, and rectal bleeding, which can lead to significant impacts on patients' daily lives, emotional wellbeing, and productivity.

Approximately 120,000 Canadians are estimated to live with UC, and its prevalence continues to rise across the country. SKYRIZI® (risankizumab) is a humanized monoclonal antibody that selectively inhibits interleukin-23 (IL-23), a key cytokine involved in inflammatory processes. SKYRIZI® is indicated for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, demonstrated dependence on corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies.

SKYRIZI® is also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to conventional therapy, biologic treatment, or a Janus kinase (JAK) inhibitor. SKYRIZI® is approved in Canada for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the treatment of adult patients with active psoriatic arthritis and it can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).